A drug originally used to boost the immune system is showing promise as a potential new treatment for lupus, joint Monash University and Peking University research published today shows. Lupus is an autoimmune disease, where the immune system attacks the body’s own organs and tissues.
An international team of scientists from Australia and China have, for the first time, shown in a study published in Nature Medicine, that a natural immune system protein called IL-2 can help restore balance to the overactive immune system of lupus patients. The drug could soon be rolled out for clinical trials in lupus treatment.
Monash Biomedicine Discovery Institute researcher, Dr Di Yu and Professor Zhanguo Li from Peking University People’s Hospital in China co-led the study.
Dr Yu said he hoped the drug could be approved as a lupus treatment within a handful of years.
“This drug, which can help the immune system fight against cancer, was approved in the 1990s but is not commonly used now. We’re now using this drug for a different purpose, based on our new knowledge of the immune system,” Dr Yu said.
“The amount we tested for treating lupus is much less than the dose used in treating cancers. We observed the treatment was safe and showed promising results, so there’s reason to believe formal trials could begin almost immediately,” he said.
Dr Yu said lupus could be a serious disease, and that it hadn’t been able to be treated in a very satisfactory way in the past.
IL-2 is a protein that regulates the activity of white blood cells, which are an important part of the immune system that protect the body against infections. In cancer therapy, patients are given large doses of IL-2 to stimulate their immune system but, paradoxically, the low dose IL-2 given to lupus sufferers in this study actually supressed the overactive part of their immune system that attacks their body. The research also showed the “self-checking” part of the immune system that prevents an overactive immune response, called regulatory T cells, increased after IL-2 treatment.
Professor Eric Morand, fellow Monash University researcher on the study and founder of the Asia Pacific Lupus Collaboration, said that in this study, IL-2 was given to people whose lupus wasn’t responding well to standard treatments.
“The real promise of this treatment is that it calms the hyperactive immune system through multiple mechanisms, which is very important as this new therapy may be effective for many patients,” Professor Morand said.
”As the drug has been on the market for some time for other diseases, it can be rapidly put into formal trials for lupus treatment right away.”
Learn more: Promising new treatment for lupus on the horizon
The Latest on: Lupus
via Google News
The Latest on: Lupus
- Cutaneous Lupus Erythematosus (CLE) Market Insights, Epidemiology and Market Forecast, 2028on October 18, 2019 at 12:49 pm
DUBLIN, Oct. 18, 2019 /PRNewswire/ -- The "Cutaneous Lupus Erythematosus (CLE) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's ...
- Easing the pain of rheumatic diseaseson October 18, 2019 at 8:48 am
Osteoarthritis, rheumatoid arthritis, lupus, gout and back pain, these are all painful conditions caused by inflammation in the body. In West Michigan there are new options. Today we have Dr. Lakshmi ...
- For People with Lupus, Organ Damage Accrual Comes with Escalating Healthcare Costs Tooon October 18, 2019 at 5:08 am
New research shows that the more organ damage a person with systemic lupus erythematosus (SLE) accrues, the higher their healthcare costs will be. In fact, the study found that those with the highest ...
- Time still left to sign up for 'Walk to End Lupus Now' this weekend in SFon October 17, 2019 at 5:27 pm
SAN FRANCISCO (KGO) -- Lupus is a disease where 90 percent of people living with lupus are women. Dr. Christine Anastasiou and Pamela Chan speak with ABC7's Kristen Sze about lupus and invite everyone ...
- Lupus Nephritis (LN): Global Growth Opportunities & Epidemiology Forecast to 2028 - ResearchAndMarkets.comon October 17, 2019 at 8:51 am
DUBLIN--(Business Wire)--The "Lupus Nephritis (LN) - Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of the ...
- Systemic Lupus Erythematosus Market An Introduction and Market Statuson October 17, 2019 at 12:10 am
Oct 17, 2019 (Market Prediction via COMTEX) -- According to ARC’s latest market research report, The global Systemic Lupus Erythematosus Market worth $2.7 billion by 2026 and growing CAGR around 7 % ...
- Research Studies Validate Superiority of Lupus Test for Clinical Decision-Making and Patient Managementon October 16, 2019 at 1:27 pm
Two studies have validated the clinical performance of the AVISE® Lupus test in patients with probable systemic lupus erythematosus (SLE) and demonstrated the superior clinical utility of the test ...
- Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facilityon October 16, 2019 at 3:30 am
Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, ...
- For Lupus, Expanding Medicaid Wasn't Enoughon October 11, 2019 at 7:34 am
States' expansion of Medicaid under the Affordable Care Act (ACA) failed to reduce preventable hospitalizations among patients with systemic lupus erythematosus (SLE), a retrospective study found. In ...
- Galectin-3 orchestrates the histology of mesentery and protects liver during lupus-like syndrome induced by pristaneon October 10, 2019 at 2:25 am
Recently, Beccaria and colleagues revealed that Lgals3 −/− developed a lupus-like disease hallmarked by intense germinal center B cells, Ig-secreting cells, and IFN-γ signature 17. Pristane (2,6,10,14 ...
via Bing News